BioPharma Resources

Drug Trial Radar · NCT07682961

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 850 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

850

Planned (sponsor's estimate)

Start

Jul 14, 2026

Primary completion

Mar 2029

Study completion Mar 2033

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Jul 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to compare how effective a long-acting injectable treatment of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) versus (CAB) and rilpivirine (RPV) injections given every 8 weeks in adults with HIV-1 whose virus is well controlled on daily oral treatment, after 1 year (52 weeks) of the treatment. The primary objective of this study are to evaluate the efficacy of switching to the regimen of LEN, TAB, and ZAB versus switching to CAB and RPV in virologically suppressed people with HIV-1 (PWH) as determined by the proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 52.

Conditions

  • HIV Infections

Interventions

  • LenacapavirDrug

    Administered subcutaneously

  • Lenacapavir TabletDrug

    Administered orally

  • TeropavimabDrug

    Administered intravenously (IV)

  • ZinlirvimabDrug

    Administered IV

  • CabotegravirDrug

    Administered intramuscular (IM)

  • RilpivirineDrug

    Administered IM

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants With HIV-1 ribonucleic acid (RNA) ≥ 50 Copies/mL at Week 52 as Defined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm.Time frame: Week 52

Locations

61 sites in 8 countries. Site status is shown where the registry gives one.

  • Franco Felizarta Md

    Bakersfield, California · Recruiting

  • Pacific Oaks Medical Group

    Beverly Hills, California · Recruiting

  • Metro Infectious Disease Consultants, P. L. L. C

    Hidden Valley Lake, California · Recruiting

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California · Recruiting

  • Optimus Medical Group

    San Francisco, California · Recruiting

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California · Recruiting

  • Yale University; School of Medicine; AIDS Program

    New Haven, Connecticut · Recruiting

  • Washington Health Institute

    Washington D.C., District of Columbia · Recruiting

  • Midland Florida Clinical Research Center, LLC

    DeLand, Florida · Recruiting

  • CAN Community Health Fort Lauderdale

    Fort Lauderdale, Florida · Recruiting

  • Midway Immunology and Research Center

    Ft. Pierce, Florida · Recruiting

  • CAN Community Health Miami Gardens

    Miami Gardens, Florida · Recruiting

  • Midland Medical

    Oakland Park, Florida · Recruiting

  • BLISS Health Inc.

    Orlando, Florida · Recruiting

  • Orlando Immunology Center, PA

    Orlando, Florida · Recruiting

  • CAN Community Health

    Sarasota, Florida · Recruiting

  • MOORE Clinical Research, Inc d/b/a TrueBlue Clinical Research

    Tampa, Florida · Recruiting

  • Triple O Research Institute, P.A.

    West Palm Beach, Florida · Recruiting

  • Atlantic Clinical Research Institute

    West Palm Beach, Florida · Recruiting

  • Grady Health System, Ponce de Leon Center

    Atlanta, Georgia · Recruiting

  • Atlanta ID Group, PC

    Atlanta, Georgia · Recruiting

  • Mercer University, Department of Internal Medicine

    Macon, Georgia · Recruiting

  • Chatham County Health Department

    Savannah, Georgia · Recruiting

  • Metro Infectious Disease Consultants

    Burr Ridge, Illinois · Recruiting

  • Howard Brown Health Center

    Chicago, Illinois · Recruiting

  • Be Well Medical Center

    Berkley, Michigan · Recruiting

  • KC CARE Health Center

    Kansas City, Missouri · Recruiting

  • AXCES Research Group, LLC

    Sante Fe, New Mexico · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • Rosedale Health and Wellness

    Huntersville, North Carolina · Recruiting

  • Wilmington Health

    Wilmington, North Carolina · Recruiting

  • University of Cincinnati College of Medicine

    Cincinnati, Ohio · Recruiting

  • North Texas Infectious Diseases Consultants, P.A.

    Dallas, Texas · Recruiting

  • Texas Centers for Infectious Disease Associates

    Forth Worth, Texas · Recruiting

  • AXCES Research Group, LLC

    Salt Lake City, Utah · Recruiting

  • Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID)

    Annandale, Virginia · Recruiting

  • TribalMed PLLC

    Seattle, Washington · Recruiting

  • Taylor Square Private Clinic

    Surry Hills, New South Wales, Australia · Recruiting

  • Momentum Clinical Research Darlinghurst

    Sydney, New South Wales, Australia · Recruiting

  • East Sydney Doctors

    Sydney, New South Wales, Australia · Recruiting

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.